UY29246A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY29246A1
UY29246A1 UY29246A UY29246A UY29246A1 UY 29246 A1 UY29246 A1 UY 29246A1 UY 29246 A UY29246 A UY 29246A UY 29246 A UY29246 A UY 29246A UY 29246 A1 UY29246 A1 UY 29246A1
Authority
UY
Uruguay
Prior art keywords
new compounds
disorders
compounds
prophylaxis
inhibitors
Prior art date
Application number
UY29246A
Other languages
English (en)
Inventor
Bogevig Anders
Lo-Alfredsson Yvonne
Pivonka Donald
Tiden Anna-Karin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36578191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0402972A external-priority patent/SE0402972D0/sv
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29246A1 publication Critical patent/UY29246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se revelan nuevos compuestos de fórmula (I) en donde R1, R12, L, ,X e Y son como se define en la memoria descriptiva y sales farmacéuticamente aceptables de los mismos junto con procesospara su preparación, composiciones que los contienen y su uso en terapia. Los compuestos son inhibidores de la enzima MPO y por ende son particularmente utiles en el tratamiento o profilaxis de trastornos neuroinflamatorios, trastornos cardiovasculares y trastornos respiratorios.
UY29246A 2004-12-06 2005-12-05 Nuevos compuestos UY29246A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0402972A SE0402972D0 (sv) 2004-12-06 2004-12-06 Novel compounds
SE0501093 2005-05-13

Publications (1)

Publication Number Publication Date
UY29246A1 true UY29246A1 (es) 2006-08-31

Family

ID=36578191

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29246A UY29246A1 (es) 2004-12-06 2005-12-05 Nuevos compuestos

Country Status (30)

Country Link
US (3) US7829707B2 (es)
EP (1) EP1824855B1 (es)
JP (1) JP5028270B2 (es)
KR (3) KR101412786B1 (es)
CN (1) CN101072778B (es)
AR (1) AR051698A1 (es)
AU (1) AU2005312388B2 (es)
BR (1) BRPI0518846B1 (es)
CA (1) CA2591314C (es)
CY (1) CY1113209T1 (es)
DK (1) DK1824855T3 (es)
ES (1) ES2390888T3 (es)
HK (1) HK1110859A1 (es)
HR (1) HRP20120781T1 (es)
IL (1) IL183182A (es)
ME (1) ME01486B (es)
MX (1) MX2007006497A (es)
MY (1) MY140748A (es)
NO (1) NO20072399L (es)
NZ (1) NZ555046A (es)
PL (1) PL1824855T3 (es)
PT (1) PT1824855E (es)
RS (1) RS52490B (es)
RU (2) RU2409578C2 (es)
SA (1) SA05260385B1 (es)
SI (1) SI1824855T1 (es)
TW (1) TWI365189B (es)
UA (1) UA89968C2 (es)
UY (1) UY29246A1 (es)
WO (1) WO2006062465A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
JP2009533426A (ja) * 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5201063B2 (ja) * 2008-04-15 2013-06-05 信越化学工業株式会社 付加硬化型シリコーン組成物及びその硬化物
MX2011009824A (es) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) * 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EA027324B1 (ru) 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
WO2013150115A1 (en) * 2012-04-05 2013-10-10 Basf Se N- substituted hetero - bicyclic compounds and derivatives for combating animal pests
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
DK2864323T3 (en) 2012-06-15 2017-08-14 Janssen Sciences Ireland Uc 1,3-DIHYDRO-2H-BENZIMIDAZOLE-2 UNDERIVATIVES SUBSTITUTED BY HETEROCYCLES AS ANTIVIRUS AGENTS AGAINST RESPIRATORY SYNCYTIAL VIRUS
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
US9920075B2 (en) 2014-09-11 2018-03-20 Bristol-Myers Squibb Company Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107531647A (zh) 2015-05-05 2018-01-02 辉瑞大药厂 2‑硫代嘧啶酮类
US10407422B2 (en) 2015-09-03 2019-09-10 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2017040451A1 (en) * 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2017160632A1 (en) * 2016-03-14 2017-09-21 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine
EP3697397A4 (en) 2017-10-19 2021-06-16 Texas State University PHOTO-ACTIVATED PROPHARMACON AGAINST CANCER
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020021300A1 (en) 2018-07-24 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml)
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021013942A1 (en) 2019-07-24 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
WO2021226161A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2024038131A1 (en) 2022-08-18 2024-02-22 Astrazeneca Ab Inhibitors of myeloperoxidase

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
US3652579A (en) * 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
SE7810947L (sv) 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4710503A (en) 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
WO1989006125A1 (en) 1987-12-31 1989-07-13 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
DK440989A (da) 1988-09-12 1990-03-13 Smithkline Beecham Corp Dopamin-beta-hydroxylase inhibitorer
JPH02160235A (ja) 1988-12-13 1990-06-20 Konica Corp ハロゲン化銀カラー写真画像の形成方法
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5100906A (en) 1990-04-19 1992-03-31 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
FR2665636B1 (fr) 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
US6046019A (en) 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US5281209A (en) 1992-06-30 1994-01-25 The Procter & Gamble Company Absorbent article having tucked flaps
JPH07507062A (ja) 1992-04-21 1995-08-03 バイオクリスト・ファーマシューティカルズ・インコーポレイテッド ７−二置換−メチル−４−オキソ−３Ｈ，５Ｈ−ピロロ［３，２−ｄ］ピリミジンおよび医薬上の用途ならびにそれを含有してなる組成物
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
ES2104424T3 (es) 1993-11-26 1997-10-01 Pfizer Compuestos de isoxazolina como agentes antiinflamatorios.
US5489598A (en) 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
WO1996018399A1 (en) 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
WO1996018400A1 (en) 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US5756511A (en) 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US5976823A (en) 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
EP1666041A3 (en) 1997-09-05 2008-04-02 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating neurodegenerative disorders
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
EP1169321A4 (en) 1999-04-02 2002-10-30 Euro Celtique Sa PURINE DERIVATIVES WITH PHOSPHODIESTERASE INHIBITOR ACTIVITY
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
FR2811989A1 (fr) 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
US6855817B2 (en) 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
FR2819723B1 (fr) 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
SE0103766D0 (sv) 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
IL158462A0 (en) 2001-05-08 2004-05-12 Astrazeneca Ab An assay for detecting inhibitors of the enzyme myeloperoxidase
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
KR101098209B1 (ko) 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
SE0302756D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
AU2004285013A1 (en) 2003-10-31 2005-05-12 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
BRPI0507604A (pt) 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
JP2009539829A (ja) 2006-06-05 2009-11-19 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼ阻害剤としてのピロロ［３，２−ｄ］ピリミジン−４−オン誘導体
AR066936A1 (es) 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CA2591314A1 (en) 2006-06-15
BRPI0518846A2 (pt) 2008-12-09
EP1824855A1 (en) 2007-08-29
MX2007006497A (es) 2007-06-22
EP1824855A4 (en) 2010-12-08
TWI365189B (en) 2012-06-01
HRP20120781T1 (hr) 2012-10-31
KR20070090178A (ko) 2007-09-05
MY140748A (en) 2010-01-15
AR051698A1 (es) 2007-01-31
NZ555046A (en) 2010-08-27
NO20072399L (no) 2007-08-24
JP2008522968A (ja) 2008-07-03
AU2005312388A1 (en) 2006-06-15
SI1824855T1 (sl) 2012-11-30
WO2006062465A1 (en) 2006-06-15
US8859568B2 (en) 2014-10-14
SA05260385B1 (ar) 2009-02-25
CN101072778B (zh) 2011-06-15
RS52490B (en) 2013-02-28
JP5028270B2 (ja) 2012-09-19
AU2005312388B2 (en) 2009-10-29
US20080221136A1 (en) 2008-09-11
RU2010139806A (ru) 2012-04-10
EP1824855B1 (en) 2012-08-08
KR101412786B1 (ko) 2014-06-30
TW200626601A (en) 2006-08-01
UA89968C2 (uk) 2010-03-25
KR20140010177A (ko) 2014-01-23
BRPI0518846B1 (pt) 2022-04-05
PL1824855T3 (pl) 2012-11-30
HK1110859A1 (en) 2008-07-25
ME01486B (me) 2014-04-20
US20150099769A1 (en) 2015-04-09
RU2007119307A (ru) 2009-01-20
KR20130037236A (ko) 2013-04-15
KR101557715B1 (ko) 2015-10-06
PT1824855E (pt) 2012-10-09
CN101072778A (zh) 2007-11-14
ES2390888T3 (es) 2012-11-19
US7829707B2 (en) 2010-11-09
DK1824855T3 (da) 2012-10-15
KR101412939B1 (ko) 2014-06-26
CY1113209T1 (el) 2016-04-13
US9580429B2 (en) 2017-02-28
CA2591314C (en) 2011-06-21
RU2409578C2 (ru) 2011-01-20
IL183182A0 (en) 2007-09-20
IL183182A (en) 2012-02-29
US20110059996A1 (en) 2011-03-10
RU2577858C2 (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
UY29246A1 (es) Nuevos compuestos
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
EA200802213A1 (ru) Способы лечения заболеваний крови
CR8744A (es) Compuestos terapeuticos
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
PA8680701A1 (es) Derivados de oxindol
SE0202463D0 (sv) Novel compounds
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
UA96277C2 (en) Benzimidazole derivatives
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161208